Officials said case-by-case evaluation of pending pricing cases is nearly complete, while DRAP is examining rules that may affect fair price determination and confirmed adequate supplies of the WHO-recommended trivalent flu vaccine.
Officials said case-by-case evaluation of pending pricing cases is nearly complete, while DRAP is examining rules that may affect fair price determination and confirmed adequate supplies of the WHO-recommended trivalent flu vaccine.